Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0136-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0135-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0134-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0133-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0132-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0131-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0130-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0129-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0128-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0127-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0126-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0125-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0124-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0123-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0122-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0121-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0120-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0119-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0118-2025Class IIIOngoingDec 18, 2024JavygtorFailed Impurities/Degradation SpecificationsDr. Reddy's Laboratories, Inc. · D-0117-2025Class IITerminatedDec 18, 2024Hylenex recombinantcGMP Deviations: Temperature excursionMckesson Medical-Surgical Inc. Corporate Office · D-0116-2025Class IITerminatedDec 18, 2024Kirkland Severe Cold & Flu Plus Congestion: Day - 112 coated caplets blister packCGMP Deviations: Released product should have been rejected.LNK International, Inc. · D-0115-2025Class IIOngoingDec 18, 2024Timolol Maleate Ophthalmic Solution USPDefective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.FDC Limited · D-0114-2025Class IIITerminatedDec 18, 2024VarithenaDefective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10...Biocompatibles UK, Ltd. · D-0113-2025Class IITerminatedDec 11, 2024Lisdexamfetamine Dimesylate CapsulesFailed Content Uniformity Specifications: Product failed to meet the action limits for stratified content uniformity.Lannett Company Inc. · D-0112-2025Class IIOngoingDec 11, 202410 Irregular PigmentationCGMP Deviations: Inconsistency in the water systems.Generitech Corporation · D-0111-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0110-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0109-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0108-2025Class IIOngoingDec 11, 2024Duloxetine DR Capsules USP 60 mgCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0107-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0106-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0105-2025Class IIOngoingDec 11, 2024Sunitinib Malate CapsulesLabeling: Label Mix-UpAvKARE · D-0104-2025Class IIOngoingDec 11, 2024Sunitinib Malate CapsulesLabeling: Label Mix-UpAvKARE · D-0103-2025Class IIIOngoingDec 11, 2024Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mgLabeling: Not Elsewhere Classified - Wrong NDC numberZydus Pharmaceuticals (USA) Inc · D-0102-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0101-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0100-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0099-2025Class IIOngoingDec 11, 2024Diltiazem Hydrochloride Extended-Release CapsulescGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0098-2025Class IIOngoingDec 11, 2024Diltiazem Hydrochloride Extended-Release CapsulescGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0097-2025